How Does Bupropion-Naltrexone Work for Weight Loss?

Bupropion-naltrexone is a prescription combination medication approved for chronic weight management in adults with obesity or overweight who have at least one weight-related health condition. Sold under the brand name Contrave in the United States, it pairs two older drugs that each affect appetite and reward signaling in the brain, producing weight loss that, in large clinical trials, averaged roughly five to six percent of body weight over a year. That number sits below what newer injectable medications can deliver, but the combination has a distinct mechanism, an oral dosing format, and a safety profile that make it a relevant option for a specific slice of people trying to manage their weight.

How the Two Drugs Work Together

Bupropion and naltrexone each do something useful on their own, but together they amplify each other in a way that neither achieves alone. Bupropion is a norepinephrine-dopamine reuptake inhibitor, meaning it raises levels of those two neurotransmitters in the brain. Among other things, this stimulates a group of neurons in the hypothalamus called POMC neurons, which are involved in suppressing appetite and increasing energy expenditure. The problem is that when POMC neurons fire, they also release a chemical called beta-endorphin, which loops back and dampens their own activity. Naltrexone, an opioid receptor blocker, steps in and prevents that self-braking signal, allowing the appetite-suppressing effect to keep going.¹

The combination also appears to change how the brain responds to food cues. Neuroimaging research has shown that bupropion-naltrexone dampens the hypothalamic response to images of food, which is the brain region that integrates hunger and satiety signals.² Separately, the drug combination alters functional connectivity in brain networks related to attention and reward processing. The bupropion component enhances dopaminergic activity in reward circuits, while the opioid blockade from naltrexone modulates the mesolimbic reward pathway. Together, this may reduce the pull that food cues exert on behavior, making it easier to resist eating beyond what you need.³

Weight Loss in Clinical Trials

The approval of bupropion-naltrexone rested on a series of large phase 3 trials collectively called the COR (Contrave Obesity Research) program. In COR-I, participants taking the higher-dose combination (naltrexone 32 mg plus bupropion 360 mg daily) lost an average of about six percent of their body weight over 56 weeks, compared to roughly one percent in the placebo group. Almost half of those on the drug lost at least five percent of their starting weight, versus about one in six on placebo.⁴

COR-II showed a similar pattern. Weight loss in the drug group reached about six and a half percent at 28 weeks and held at roughly six percent at 56 weeks. The placebo group barely budged beyond one to two percent. A significantly larger share of people on the combination hit the five, ten, and fifteen percent weight-loss thresholds compared to placebo at both time points.⁵

These are averages, and averages can be misleading. Some people respond strongly and lose well over ten percent of their body weight; others see little change. The trial data suggest that early response is a useful signal. A threshold of five percent weight loss by week 16 correctly predicted about 80 percent of participants who would or would not reach that same five percent mark at week 56.⁶ That is why prescribing guidelines typically recommend stopping the medication if you have not lost at least five percent of your body weight by about four months.

Benefits Beyond the Scale

In people with type 2 diabetes, bupropion-naltrexone has shown meaningful improvements in blood sugar control. In the COR-Diabetes trial, participants on the drug saw their HbA1c drop by about 0.6 percentage points compared to 0.1 in the placebo group, and a larger share achieved HbA1c levels below seven percent. The drug group also had improvements in triglycerides and HDL cholesterol.⁷

A meta-regression analysis looking at bupropion alone and in combination with naltrexone across multiple studies confirmed reductions in fasting glucose, insulin levels, insulin resistance, and triglycerides, along with increases in HDL cholesterol.⁸ These metabolic improvements likely reflect the weight loss itself, but they matter for people whose reason for seeking treatment goes beyond cosmetic concern. If you are prediabetic or managing early type 2 diabetes alongside obesity, this medication can nudge multiple risk markers in the right direction simultaneously.

Quality-of-life scores also improve more on the drug than on placebo. In a pooled analysis, people taking bupropion-naltrexone reported larger improvements on a validated weight-related quality-of-life measure, and half of drug-treated participants achieved what researchers consider clinically meaningful improvement, compared to about a third on placebo.⁹

What Side Effects to Expect

Nausea is the most common complaint, and it is worth being specific about what that looks like in practice. Pooled analysis of the trial data shows that the nausea is nearly always mild to moderate, tends to appear during the dose-escalation period in the first few weeks, and generally resolves on its own or with simple management like staying hydrated and avoiding excess caffeine.¹⁰ Clinicians sometimes slow the dose ramp-up beyond what the label suggests, keeping patients on a single daily tablet through the second week instead of immediately stepping up. That approach lacks randomized trial data, but clinical experience supports it as a reasonable strategy for people who are struggling early on.

Other commonly reported side effects include constipation, headache, dizziness, dry mouth, and insomnia. The drug is generally well tolerated, with nausea leading the list of adverse events.¹¹ Most of these side effects are dose-related and tend to settle as the body adjusts.

Cardiovascular Safety

Bupropion can modestly raise blood pressure and heart rate, and that concern prompted the FDA to require a large cardiovascular outcomes trial. The LIGHT trial enrolled people with overweight or obesity who already had cardiovascular risk factors. A post hoc analysis at 16 weeks, when patients were still consistently taking the drug, found that blood pressure increased by less than half a millimeter of mercury on average, and heart rate increased by less than half a beat per minute compared to placebo.¹² These are small differences, but the trial was ultimately terminated early due to a data leak, leaving the cardiovascular question less definitively answered than anyone would have liked. In practice, prescribers monitor blood pressure during treatment and discontinue the drug if sustained increases occur. Guidelines suggest stopping if systolic or diastolic blood pressure rises by 10 mmHg or more.¹³

Psychiatric Safety and Mood

Because bupropion is also an antidepressant, the combination carries the class-wide black box warning about suicidal thoughts in young adults. The clinical trial data, however, do not show an increased risk of suicidality with this combination. In a pooled analysis of over 3,200 people on the drug and 1,500 on placebo, there were no completed suicides or suicide attempts in either group. Suicidal ideation occurred in one person on the drug versus three on placebo.¹⁴

Sleep disturbance is the psychiatric side effect that clearly differs between drug and placebo. About 13 percent of people on bupropion-naltrexone reported sleep problems, compared to about eight percent on placebo. Anxiety and depression rates were broadly similar between groups, though a small but statistically significant difference in anxiety was noted (about five percent on the drug versus three percent on placebo).¹⁵ A separate pooled analysis that specifically focused on people with overweight or obesity who already had depressive symptoms found no difference in psychiatric adverse events, worsening depressive symptoms, or suicidal ideation between the drug and placebo groups.¹⁶ The original COR-I trial also reported no association between the combination treatment and increased depression or suicidality events compared with placebo.¹⁷

Binge-Eating Disorder

Given that bupropion-naltrexone acts on reward circuits in the brain, an obvious question is whether it helps people with binge-eating disorder. The evidence here is genuinely mixed and worth unpacking. One randomized trial found that binge-eating frequency dropped significantly in both the drug and placebo groups, with no clear advantage for the medication.¹⁸ However, a different trial that tested the drug alongside behavioral weight-loss therapy found that bupropion-naltrexone was significantly better than placebo for binge-eating remission, with a remission rate of about 31 percent on the drug alone versus about 18 percent on placebo. When the drug was combined with behavioral therapy, remission jumped to 57 percent.¹⁹

A recent meta-analysis pooling three studies concluded that bupropion-naltrexone did not significantly reduce binge-eating frequency overall, but it did produce significant weight loss and BMI reduction in people with the disorder.²⁰ So the medication may not directly stop binge episodes, but it can still help people with binge-eating disorder lose weight and may work synergistically with structured behavioral treatment for the eating pattern itself. This is a case where the drug should probably not be the only intervention, but it is not useless either.

What Happens When You Stop

Weight regain after stopping anti-obesity medications is a consistent finding across the class, and bupropion-naltrexone is no exception. A meta-analysis examining the trajectory of body weight after drug discontinuation across multiple anti-obesity medications found that in the first month off treatment, the residual weight-loss effect was still detectable. But by eight weeks after stopping, weight regain became statistically significant, and the trend continued at 12 and 20 weeks.²¹ This does not mean the medication is pointless, but it does mean that bupropion-naltrexone works while you take it, much like blood-pressure medication controls blood pressure while you take it. The implication is that for many people, treatment may need to be long-term if the goal is sustained weight management.

Real-World Results Outside Clinical Trials

Clinical trial populations are selected, motivated, and monitored in ways that everyday patients are not. Real-world data offer a useful reality check. A study tracking people prescribed bupropion-naltrexone in routine clinical practice found that about 47 percent of surgery-naive patients were still taking the drug at four months, with a median weight loss of about six percent. At 12 months, roughly 39 percent remained on the medication, and those who persisted had a median weight loss of nearly nine percent. Interestingly, whether patients reached the maximum dose did not significantly influence how much weight they lost.²²

The same study also looked at people who had previously undergone bariatric surgery and were regaining weight. Their persistence was higher: about 63 percent were still on the drug at 12 months, with a median weight loss of about 10 percent. This suggests that bupropion-naltrexone may be a useful adjunct for weight regain after bariatric procedures, a scenario that clinicians increasingly encounter and have limited tools for.

The dropout rate is the unsurprising part of these numbers. Side effects, cost, and the modest pace of weight loss compared to what people hear about newer injectables all contribute to early discontinuation. The people who stick with it tend to do reasonably well.

Drug Interactions and Surgical Considerations

Because naltrexone blocks opioid receptors, the most important practical concern is the interaction with opioid medications. If you are taking any opioid for chronic pain, starting bupropion-naltrexone can trigger acute opioid withdrawal. An observational study reviewing adverse event cases found that among 23 people who started the combination while on opioid therapy and had documented outcomes, about three-quarters experienced serotonin syndrome, opioid withdrawal, or both, and most of these cases had at least a moderate clinical impact.²³ This is not a subtle risk. You must be completely off opioids before starting the medication, and prescribers should verify this.

Surgery presents another challenge. If you need a procedure and will require opioid-based pain control, the naltrexone component will block those drugs from working properly. Patients taking bupropion-naltrexone who present for surgery require advance planning with their surgical and anesthesia teams to arrange alternative pain management strategies.²⁴ This typically means stopping the medication well before a planned surgery to allow opioid receptors to become available again. For emergency surgery, non-opioid pain strategies, regional anesthesia, and close monitoring become essential.

Beyond opioids, bupropion lowers the seizure threshold, so the combination is contraindicated in people with seizure disorders, eating disorders involving purging (which can cause electrolyte imbalances that further lower the threshold), or those undergoing abrupt withdrawal from alcohol or benzodiazepines. It also should not be combined with monoamine oxidase inhibitors.

Early Signals From Alcohol Research

Both bupropion and naltrexone are individually used in treating substance use disorders. Naltrexone is FDA-approved for alcohol use disorder, and bupropion is approved for smoking cessation. Their combination has naturally drawn interest as a potential treatment for heavy drinking. Preclinical work in alcohol-preferring rats found that when low doses of naltrexone and bupropion were given separately, neither reduced alcohol intake. Combined, they significantly reduced drinking.²⁵

Follow-up work in mice introduced a complication worth noting: the combination reduced alcohol intake in males but not in females. In male mice, the combination also reduced intake of sucrose (a caloric reward) but not saccharin (a non-caloric reward), hinting that the effect may be driven by the caloric reward value of alcohol rather than its pharmacological effects alone.²⁶ These are animal studies, and no randomized human trials of bupropion-naltrexone for alcohol use disorder have been completed. But the overlap between the brain pathways involved in food reward and alcohol reward makes this a plausible avenue for future research, and some clinicians already consider the combination informally when a patient has both obesity and problematic drinking.

How the Dosing Works

The approved formulation uses extended-release versions of both drugs. The target dose is two tablets twice a day, each tablet containing naltrexone 8 mg and bupropion 90 mg, for a daily total of naltrexone 32 mg and bupropion 360 mg. You do not start at the full dose. The standard ramp-up adds one tablet per week over four weeks:

Week 1: one tablet in the morning
Week 2: one tablet morning and evening
Week 3: two tablets in the morning, one in the evening
Week 4 onward: two tablets morning and evening

This gradual escalation is meant to reduce nausea and other early side effects. As mentioned earlier, some prescribers stretch the escalation even further for sensitive patients. The real-world evidence suggesting that reaching the maximum dose does not significantly affect weight loss outcomes is interesting in this context. Some patients may find a lower dose sufficient and better tolerated, though this has not been rigorously studied in a dose-finding way.²⁷

Who It Is and Isn’t Right For

Bupropion-naltrexone occupies a specific niche. It is approved for adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition like hypertension, type 2 diabetes, or high cholesterol. It is not approved for use in children or adolescents, and the clinical trials were conducted in adults.

Several groups should not take the drug: people with uncontrolled hypertension, seizure disorders, current opioid use, those in acute withdrawal from alcohol or sedatives, anyone with a history of bulimia or anorexia nervosa, or those taking monoamine oxidase inhibitors. People with moderate to severe hepatic impairment also need dose adjustments or should avoid it entirely.

For people who cannot tolerate or access the newer GLP-1 receptor agonist injections, bupropion-naltrexone is one of a small number of oral options. Its place in the landscape is probably strongest for patients who also have depressive symptoms (since bupropion has antidepressant properties and the combination has not worsened depression in trials), or for those who want an oral medication and are comfortable with a more modest weight-loss outcome. The combination of a quality-of-life improvement signal,²⁸ metabolic benefits, and a well-characterized safety profile makes it a reasonable choice for the right patient, even if it is no longer the headline-grabbing option it was before semaglutide and tirzepatide arrived.